Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer

Compensatory activation of the signal transduction pathways is one of the major obstacles for the targeted therapy of non‐small cell lung cancer (NSCLC). Herein, we present the therapeutic strategy of combined targeted therapy against the MEK and phosphoinositide‐3 kinase (PI3K) pathways for acquire...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Hiroki, Yamamoto, Hiromasa, Sakaguchi, Masakiyo, Shien, Kazuhiko, Tomida, Shuta, Shien, Tadahiko, Ikeda, Hirokuni, Hatono, Minami, Torigoe, Hidejiro, Namba, Kei, Yoshioka, Takahiro, Kurihara, Eisuke, Ogoshi, Yusuke, Takahashi, Yuta, Soh, Junichi, Toyooka, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172047/
https://www.ncbi.nlm.nih.gov/pubmed/30098066
http://dx.doi.org/10.1111/cas.13763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172047/
https://www.ncbi.nlm.nih.gov/pubmed/30098066
http://dx.doi.org/10.1111/cas.13763

Ejemplares similares